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ABSTRACT
We retrospectively analyzed outcomes among 307 consecutive patients who had recurrent or persistent acute
leukemia (n 244), chronic myelogenous leukemia in blast phase (CML; n 28), or advanced myelodysplastic
syndromes (MDS; n  35) after allogeneic hematopoietic cell transplantation and who received at least 1
relapse-directed intervention: withdrawal of immunosuppression, chemotherapy, or donor lymphocyte infu-
sion (DLI). Transplants were performed at a single institution between 1995 and 2004, and outcomes were
analyzed according to time intervals from transplantation to detection of malignancy: “early,” <100 days (n 
111); “intermediate,” 100-200 days (n  73); and “late,” >200 days (n  123). The overall remission rate was
30%. Compared to early recurrence, intermediate recurrence and late recurrence were associated with
increasing probabilities of remission (hazard ratios, 1.89 and 2.16; P  .05 and .02) and decreasing risks of
overall mortality (hazard ratios, 0.73 and 0.33; P  .05 and <.0001). The 2-year overall survival (OS) estimates
for patients with early, intermediate, and late recurrence were 3%, 9%, and 19%, respectively. Remission was
associated with a median survival prolongation of 9.5 months. Individual types or combinations of these
nonrandomly assigned relapse-directed interventions were not associated with higher or lower probabilities of
remission or survival. More effective intervention strategies are needed for treatment of recurrent high-risk
hematologic malignancies after hematopoietic cell transplantation. In the absence of innovative clinical trials,
patients with early recurrence might wish to forego further interventions in favor of palliative care.
© 2007 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Recurrence or persistence of aggressive hemato-
ogic malignancies after allogeneic hematopoietic cell
ransplantation (HCT) indicates the emergence of
alignant cells that are resistant to the conditioning
egimen, which results in a high mortality rate
1-6]. In theory, the likelihood of successful remis-
ion-induction in patients with recurrent malig-
ancy after allogeneic HCT depends on (1) the
roliferative rate of the malignant cells, (2) their
usceptibility to immunologic graft-versus-leuke-
ia (GVL) effects, (3) their susceptibility to addi-ional chemotherapy, and (4) the toxicity of the d
160reatment, which may cause mortality before attain-
ent of remission.
At least 5 approaches can be considered for man-
gement of recurrent malignancy after allogeneic
CT. First, in the absence of graft-versus-host dis-
ase (GVHD), the induction of immunologic GVL
ffects can be attempted by withdrawing immunosup-
ressive drugs. Second, for patients who are medically
t to tolerate additional cytotoxic therapy, reinduc-
ion-chemotherapy can be administered. Third, if im-
unosuppressive therapy has been tapered without
evelopment of clinically relevant GVHD, donor
ymphocyte infusion (DLI) from the original stem cell
onor can be given. In clinical practice, chemotherapy
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Recurrent Leukemia after Allografting 1161s frequently combined with interventions that might
nduce GVL effects. Fourth, in some patients, it might
e possible to treat the malignancy with another trans-
lant, either from the same donor or a different donor.
ifth, when malignancy recurs after development of
VHD, or when comorbidity precludes further che-
otherapy, supportive care can be continued without
ttempting to induce remission.
Although the immunologic GVL effects associ-
ted with the withdrawal of immunosuppressive med-
cations and DLI are most evident in patients with
ecurrent chronic myelogenous leukemia (CML) in
hronic phase [7,8], these interventions have been
ubstantially less effective for management of recur-
ent malignancies that are more aggressive, including
cute leukemias and advanced myelodysplastic syn-
romes (MDS) [2,9-13]. Nevertheless, the encourag-
ng experience with DLI among patients with recur-
ent CML in chronic phase has led to the continued
se of DLI in patients with other hematologic malig-
ancies [14].
Detailed knowledge of the risk-beneﬁt ratio of any
herapeutic intervention is needed in order to make
easonable clinical decisions. This information is also
eeded in order to counsel patients and direct research
fforts. The beneﬁts and risks associated with inter-
entions used for the treatment of patients with re-
urrent aggressive hematologic malignancies follow-
ng allogeneic HCT, however, are poorly deﬁned. We
herefore retrospectively analyzed outcomes among
07 consecutive patients with recurrent or persistent
cute leukemia and advanced MDS who received re-
apse-directed interventions at a single institution. We
ound that remission was attained in 30% of patients,
nd remission was associated with a median survival
rolongation of approximately 9 months. The 2-year
urvival estimate, however, was only 3% when the
alignancy recurred100 days from HCT. Our ﬁnd-
ngs underscore the urgent need for more effective
anagement strategies for patients with recurrent
igh-risk hematologic malignancy after allogeneic
CT.
ATIENTS AND METHODS
ligibility Criteria
Patients had signed forms approved by the insti-
utional review board documenting informed consent
o participate in the clinical trials and to allow the use
f medical information for research. The study in-
luded all patients with acute myelogenous leukemia
AML), acute lymphocytic leukemia (ALL), chronic
yelogenous leukemia in blast-phase (CML-BP), or
dvanced MDS (refractory anemia with excess blasts
ith or without transformation; RAEB or RAEBt)
ho had ﬁrst allogeneic transplants from related or gnrelated donors at the Fred Hutchinson Cancer Re-
earch Center (FHCRC) between January 1995 and
ecember 2004, had detectable malignant cells in the
one marrow after transplantation, and were at least
8 years of age at the time of transplantation. The
ematologic malignancies included in this analysis
ere deemed “high-risk” by virtue of early fatality
nless remission is attained. The study included all
atients known to have detectable malignancy after
ransplantation, regardless of whether the malignancy
as discovered by the transplant center or by the
eferring physician. Evidence of malignant cells in the
one marrow was assessed by morphologic, ﬂow cy-
ometric, cytogenetic, or molecular criteria. To be
ncluded in the ﬁnal analysis, detectable malignancy
fter transplantation had to be treated by at least 1 of
interventions: (1) withdrawal of immunosuppression
WIS), (2) chemotherapy, or (3) DLI. According to
hese criteria, 307 patients qualiﬁed for analysis in
ovember 2006.
ransplantation Regimens
Myeloablative group. Patients in the myeloablative
roup were prepared according to different high-dose
reparative regimens with or without total-body irra-
iation (TBI) [15,16]. Busulfan levels were targeted to
00-900 ng/mL. As prophylaxis against GVHD, most
atients (82%) were given cyclosporine (CSP) plus
ethotrexate (MTX) as described previously [17]. Six
ercent received CSP in combination with mycophe-
olate mofetil (MMF) [18] and 14% were given other
egimens.
Nonmyeloablative group. Patients in the nonmyeloa-
lative group received low-dose TBI (2 Gy) alone or
n combination with ﬂudarabine (30 mg/m2 body sur-
ace area/day, for 3 consecutive days) [19,20]. Post-
rafting immunosuppression included MMF and
SP, as described previously [20,21].
ollection of Hematopoietic Cells and
upportive Care
Patients who had myeloablative conditioning re-
eived either bone marrow (42%) or granulocyte-
olony stimulating factor (G-CSF)-mobilized periph-
ral blood mononuclear cells (G-PBMC) (58%). Most
atients who had nonmyeloablative conditioning
ere given G-PBMC (88%); 12% were given bone
arrow cells. Antimicrobial and antiviral prophy-
axis and blood product support were administered
s described [22].
nterventions for the Treatment of Detectable
alignancy after Transplantation
WIS. Any attempt aimed at inducing immunologic
raft-versus-tumor effects by tapering the doses of
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M. Mielcarek et al.1162mmunosuppressive medications or by discontinuing
heir administration was categorized as “WIS.”
Chemotherapy. Any means of cytotoxic therapy
imed at remission-induction or cytoreduction was
ategorized as “chemotherapy.” Interventions cate-
orized as “chemotherapy” included combination
herapies such as cytarabine/anthracycline, mitox-
ntrone/etoposide, and single-agent therapies such
s high-dose cytarabine, imatinib, and gemtuzumab
zogamycin.
Immunomodulatory treatment of patients with
ML with interferon was also categorized as “chemo-
herapy.”
DLI. DLI was typically administered to patients
ho had discontinued systemic immunosuppressive
herapy without developing clinically signiﬁcant
VHD. For recipients of related and unrelated grafts,
he typical T cell doses used for the initial infusion
ere 1  108 and 1  107 CD3 cells per kg, respec-
ively. In the absence of ensuing GVHD and as per-
itted by the clinic circumstances, a 1-log dose esca-
ation was typically used for the second DLI. Donor
ymphocytes were collected by leukapheresis without
rowth factor mobilization. Cells collected for DLI
rom related donors were infused on the day of col-
ection. Cells from most unrelated donors were cryo-
reserved at the time of stem cell collection before the
ransplant.
Recipients of allogeneic transplants typically stay
n Seattle under the care of the FHCRC for approx-
mately 100 days after transplant. Most patients with
ecurrent malignancy within 100 days from transplan-
ation who had interventions were therefore treated in
eattle. After discharge from our Center, a dedicated
ong-Term Follow-Up group continued to provide
uidance for oncologists and patients. Thus, decisions
ertaining to modulation of immunosuppression and
dministration of chemotherapy were usually made
ccording to recommendations of a long-term fol-
ow-up physician at our Center. Patients who were
onsidered candidates for DLI were asked to return to
ur Center for evaluation and treatment.
efinition of Remission
For assessing outcomes after WIS, chemotherapy,
nd DLI, remission was deﬁned as disappearance of
ny evidence that leads to the diagnosis of recurrent or
ersistent malignancy before the intervention. For
ategorizing patients before administration of DLI,
emission was deﬁned as the presence of 5% blasts
n the marrow by morphologic examination.
VHD Grading and Treatment
Grading and treatment of acute and chronic
VHD (aGVHD, cGVHD) was done as previously
escribed [22,23]. Patient records were also reviewed dor evidence of serious GVHD [24] after interventions
or recurrent malignancy.
tatistic Analysis
Survival curves were estimated by the Kaplan-
eier method. Cumulative incidence curves were es-
imated according to previously described methods
25]. Survival and time to remission were analyzed
sing Cox regression. In the analysis of survival, DLI
nd remission were treated as time-dependent covari-
tes; DLI was treated as a time-dependent covariate in
he analysis of time to remission. The estimated in-
rease in survival associated with attainment of remis-
ion was estimated as the difference between (a) the
edian survival after complete remission (CR) among
atients who had remission, and (b) the estimated
edian survival of the same patients when the in-
erse of the hazard ratio (HR) associated with re-
ission was applied to the survival function from
he same time point. All P-values are 2-sided and
efer to HR analyses.
The selected time points for grouping patients
ith recurrent malignancy after transplantation (100
ays, 100-200 days, 200 days) were prespeciﬁed.
hey represent uniform 100 day-intervals that ap-
roximate a tertile distribution. The grouping in 100-
ay intervals was of practical relevance, because pa-
ients typically stay under the care of our Center until
00 days after transplantation.
ESULTS
atient and Treatment Characteristics
Between January 1995 and December 2004, 1111
atients had allogeneic HCT for AML (n  679),
LL (n 208), CML-BP (n 75), or advanced MDS
n  149). Of those, 374 (35%) had recurrent malig-
ancy after transplant; 307 patients received at least 1
elapse-directed intervention and were included in
his analysis. Among those treated, 185 (60%) had
ML, 59 (19%) had ALL, 35 (11%) had RAEB/t, and
8 (9%) had CML-BP. The median time from HCT
o recurrent malignancy was 152 (range: 15-3493)
ays. Time intervals from HCT to recurrent malig-
ancy were 100 days for 111 patients, 100-200 days
or 73 patients, and200 days for 123 patients (Table 1).
IS was less frequent when malignancy recurred
200 days after HCT, because many of these patients
ad already completed the planned posttransplant im-
unosuppressive regimen. The proportion of patients
ho received chemotherapy increased with longer
ime intervals from HCT to recurrent malignancy,
ost likely reﬂecting ability to tolerate this treatment
fter recovery from effects of the pretransplant con-
itioning regimen. DLI was used more frequently
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Recurrent Leukemia after Allografting 1163hen the interval from HCT to recurrent malignancy
as 200 days.
actors Associated with Attainment of Remission
Longer intervals from HCT to recurrence of ma-
ignancy were associated with higher incidence rates
f subsequent remission (Table 1 and Figure 1A). The
umulative incidence of remission at 6 months from
elapse was 18% among patients who had recurrent
alignancy 100 days from HCT, compared to 37%
mong those with recurrent malignancy 200 days
rom HCT. Among the 61 patients who had recur-
ence more than 1 year after HCT, 26 (43%) had a
ubsequent remission, suggesting no further major
able 1. Characteristics of Patients with Recurrent High-Risk
ematologic Malignancy after Allogeneic Hematopoietic Cell
ransplantation
Transplantation-to-Relapse Interval
(Days)
<100 100-200 >200
111 73 123
iagnosis, n (%)
AML 71 (64) 45 (62) 69 (56)
ALL 12 (11) 13 (18) 34 (28)
CML-BP 13 (12) 8 (11) 7 (6)
RAEB/t 15 (14) 7 (10) 13 (11)
edian age, years
(range) 46 (18-74) 40 (19-70) 40 (18-67)
onor type, n (%)
HLA-matched sibling 48 (43) 34 (47) 65 (53)
Other 63 (57) 39 (53) 58 (47)
reparative regimen,
n (%)
Myeloablative 88 (79) 65 (89) 113 (92)
Nonmyeloablative 23 (21) 8 (11) 10 (8)
onor/ patient sex,
n (%)
Female/male 26 (23) 17 (23) 32 (26)
Other 85 (77) 56 (77) 91 (74)
rior acute GVHD, n (%)
Grade 0/1 29 (26) 17 (23) 27 (22)
Grade 2 82 (74) 56 (77) 96 (78)
elapse-directed
intervention, n (%)
WIS only 45 (41) 13 (18) 12 (10)
Chemotherapy only 15 (14) 16 (22) 71 (59)
Both 50 (45) 44 (60) 37 (31)
LI, n (%)
No 95 (86) 61 (84) 86 (70)
Yes 16 (14) 12 (16) 37 (30)
ttainment of remission,
n (%)
No 91 (82) 49 (67) 74 (60)
Yes 20 (18) 24 (33) 49 (40)
ML indicates acute myelogenous leukemia; ALL, acute lympho-
blastic leukemia; CML-BP, chronic myelogenous leukemia in
blast phase; RAEB/t, refractory anemia with excess blasts/ in
transformation; GVHD, graft-versus-host disease; WIS, with-
drawal of immunosuppression; DLI, donor lymphocyte infu-
sion.dvantage for later recurrence beyond 200 days. Mul- eivariate analysis conﬁrmed the association of longer
ntervals from HCT to recurrent malignancy with a
igher probability of subsequent remission (Table 2).
atients with recurrent malignancy after day 200 had
2-fold higher probability of remission (HR 2.16,
5% conﬁdence interval [CI] 1.2-4.0; P  .02) com-
ared to those who had recurrent malignancy within
he ﬁrst 100 days after HCT. The multivariate anal-
sis also showed that a diagnosis of advanced MDS
igure 1. Outcome among patients with recurrent high-risk hema-
ologic malignancy after allogeneic HCT. A, Cumulative incidence
f remission according to interval from HCT to recurrent malig-
ancy (relapse within 100 days versus 100-200 days from HCT,
 .05; relapse within 100 days versus 200 days from HCT, P 
04). B, Survival according to interval from HCT to recurrent
alignancy (relapse within 100 days versus 100-200 days from
ransplantation, P  .01; relapse within 100 days versus 200 days
rom transplantation, P .0001). The median follow-up among the
6 surviving patients is 23 (range: 2-115) months. C, Survival
ccording to conditioning intensity (myeloablative versus nonmy-
loablative) and interval from HCT to recurrent malignancy.
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M. Mielcarek et al.1164as associated with a decreased likelihood of remis-
ion compared to AML. The types of pretransplant
onditioning regimen and postrelapse intervention
ere not associated with the likelihood of remission in
his analysis.
actors Associated with Survival
In the course of this retrospective review, we iden-
iﬁed 67 patients who did not receive WIS, chemo-
herapy, or DLI for treatment of persistent or recur-
ent high-risk malignancy after allogeneic HCT. All
f these patients died within 200 days after malignant
ells were ﬁrst detected. Among patients who had at
east 1 of the 3 interventions, longer time intervals
rom HCT to recurrent malignancy were strongly
ssociated with prolonged survival after the diagnosis
able 2. Multivariate Analysis of Factors Associated with Attainment o
alignancy after Allogeneic Hematopoietic Cell Transplantation
ays from transplantation to relapse
<100 days
100-200 days
>200 days
iagnosis
AML
ALL
CML
RAEB/t
n relapse at transplant (among AML/ALL)
No
Yes
onor/patient sex
Others
Female/male
rior acute GVHD
Grade 0/1
Grade 2
rior extensive chronic GVHD
No
Yes
onor type
Other
HLA-matched sibling
atient age at transplant
<50 years
>50 years
reparative regimen
Myeloablative
Nonmyeloablative
elapse-directed intervention
WIS only
Chemotherapy only
Both
LI*
No
Yes
R indicates hazard ratio; CI, conﬁdence interval; AML, acute myel
myelogenous leukemia in blast phase; RAEB/t, refractory anem
WIS, withdrawal of immunosuppression; DLI, donor lymphocy
Administration of DLI was treated as time-dependent variable (Df recurrent malignancy (Figure 1B). The 2-year sur- wival estimates among patients with recurrent malig-
ancy 100 days, 100-200 days, and 200 days from
CT were 3%, 9%, and 19%, respectively (P 
0001). The survival curves for patients who had re-
urrent malignancy within consecutive 100-day inter-
als beyond 200 days from HCT were similar (data
ot shown). The time interval from HCT to recurrent
alignancy remained a powerful predictor of mortal-
ty after adjusting for diagnosis, patient age, donor
ype, donor/patient sex, presence of prior GVHD,
blative or nonmyeloablative conditioning regimen,
ype of intervention, and attainment of remission in
ultivariate analysis (Table 3). Patients with recurrent
alignancy after day 200 had a 67% reduced hazard of
ortality (HR 0.33, 95% CI 0.2-0.5; P  .0001)
ompared to those who had recurrent malignancy
sion among Patients with Recurrent High-Risk Hematologic
HR (95% CI) P
1.0
1.89 (1.0-3.5) .05
2.16 (1.2-4.0) .02
1.0
0.59 (0.3-1.0) .07
0.73 (0.4-1.5) .38
0.31 (0.1-0.8) .01
1.0
0.67 (0.4-1.2) .15
1.0
0.80 (0.5-1.3) .39
1.0
1.31 (0.8-2.2) .31
1.0
0.62 (0.4-1.0) .07
1.0
1.23 (0.8-1.9) .36
1.0
0.75 (0.4-1.4) .34
1.0
1.59 (0.7-3.7) .28
1.0
0.92 (0.5-1.9) .81
1.35 (0.7-2.6) .37
1.0
1.31 (0.7-2.6) .44
s leukemia; ALL, acute lymphoblastic leukemia; CML-BP, chronic
excess blasts/in transformation; GVHD, graft-versus-host disease;
sion.
n after attainment of remission was excluded from the analysis).f Remis
N
111
73
123
185
59
28
35
138
106
232
75
83
224
205
102
160
147
203
104
266
41
70
102
131
269
39
ogenou
ia with
te infuithin the ﬁrst 100 days after HCT. Additional factors
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Recurrent Leukemia after Allografting 1165igniﬁcantly associated with decreased hazards of
ortality were attainment of remission and diagnoses
f CML-BP or MDS (Table 3). In multivariate anal-
sis, AML or ALL remission status at the time of
ransplant was not signiﬁcantly associated with the
azard of mortality following detection of malignancy
fter transplant (Table 3). Figure 1C shows that the
ssociation between interval from HCT to recurrent
alignancy and survival applied to HCT with either
yeloablative or nonmyeloablative conditioning.
The median estimated survival gain for all patients
ho had remission was 9.4 months compared to those
ho did not have remission (Table 4). The median
able 3. Multivariate Analysis of Factors Associated with Mortality am
llogeneic Hematopoietic Cell Transplantation
ays from transplantation to relapse
<100 days
100-200 days
>200 days
iagnosis
AML
ALL
CML-BP
RAEB/t
n relapse at transplant (among AML/ALL)
No
Yes
onor/patient sex
Others
Female/male
rior acute GVHD
Grade 0/1
Grade 2
rior extensive chronic GVHD
No
Yes
onor type
Other
HLA-matched sibling
atient age at transplant
<50 years
>50 years
reparative regimen
Myeloablative
Nonmyeloablative
elapse-directed intervention
WIS only
Chemotherapy only
Both
LI*
No
Yes
ttained remission*
No
Yes
R indicates hazard ratio; CI, conﬁdence interval; AML, acute myel
myelogenous leukemia in blast phase; RAEB/t, refractory anem
WIS, withdrawal of immunosuppression; DLI, donor lymphocy
Administration of DLI and attainment of remission were treated astimated survival gains associated with remission imong patients with recurrent malignancy100 days,
00-200 days, and 200 days from HCT were 5.9,
.5, and 12.6 months, respectively.
ole of DLI
Sixty-one patients were given DLI in addition to
IS and/or chemotherapy; only 4 patients were given
LI as the only intervention. Forty-nine patients
75%) received 1 infusion, 15 patients (23%) received
infusions, and 1 patient received 3 infusions. Two of
he 4 patients given DLI with no other intervention
eveloped serious GVHD as a consequence of this
tients with Recurrent High-Risk Hematologic Malignancy after
HR (95% CI) P
1.0
0.73 (0.5-1.0) .05
0.33 (0.2-0.5) <.0001
1.0
1.24 (0.9-1.7) .21
0.43 (0.3-0.7) .0003
0.46 (0.3-0.7) .0005
1.0
1.15 (0.8-1.6) .42
1.0
1.00 (0.7-1.3) .98
1.0
1.15 (0.8-1.6) .38
1.0
1.12 (0.8-1.6) .53
1.0
0.96 (0.7-1.2) .73
1.0
1.54 (1.1-2.1) .005
1.0
0.77 (0.5-1.2) .23
1.0
1.15 (0.8-1.7) .46
0.77 (0.6-1.1) .12
1.0
0.95 (0.7-1.3) .79
1.0
0.29 (0.2-0.4) <.0001
s leukemia; ALL, acute lymphoblastic leukemia; CML-BP, chronic
excess blasts/in transformation; GVHD, graft-versus-host disease;
sion.
-dependent variables.ong Pa
N
111
73
123
185
59
28
35
138
106
232
75
83
224
205
102
160
147
203
104
266
41
70
102
131
242
65
214
93
ogenou
ia with
te infuntervention. Overall, 12 (18%) of the 65 patients who
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M. Mielcarek et al.1166ad DLI experienced serious GVHD, compared to 21
9%) of the 242 who did not have DLI (P  .02).
In multivariate analysis, use of DLI was not asso-
iated with attainment of remission or prolongation of
urvival (Tables 2 and 3). We therefore asked whether
dministration of DLI for consolidation of remission
as associated with improved survival. Ninety-one of
he 307 patients (30%) included in this analysis had
orphologic remission after WIS or chemotherapy.
mong the 91, 11 (12%) had DLI before remission
as attained, 26 (29%) had DLI after remission was
ttained, and 54 (59%) did not receive DLI. Reasons
or withholding DLI after attainment of remission
ere active GVHD (72%), severe intercurrent illness
9%), patient or physician preference (9%), recurrent
alignancy before DLI could be administered (6%),
nd second HCT (4%). The adjusted HR of survival
mong patients given DLI for remission consolidation
ompared to those not given this intervention was
.17 (95% CI, 0.6-2.2; P  .64).
econd Transplants
Six of 307 patients (2%) with recurrent malig-
ancy (AML, n  5; CML-BP, n  1) received a
econd HCT (myeloablative regimen, n  1; nonmy-
loablative regimen, n  5). These patients had re-
urrent malignancy at a median of 728 (range: 291-
833) days from the ﬁrst HCT and were given the
econd HCT at a median of 432 (range: 225-1715)
ays after recurrence. At the time of analysis, 3 of the
patients were alive and in remission at 13, 32, and 68
onths after recurrence.
erious GVHD
GVHD was deﬁned as “serious” when it resulted
n (1) death, (2) disability, (3) 3 or more major infec-
ions in 1 year, (4) prolonged hospitalization, or (5)
uicide or hospitalization for suicidal ideation [24].
hirty-one (11%) of the 307 patients had serious
VHD, including 9 (13%) of the 70 who had WIS
lone, 5 (5%) of the 102 who had chemotherapy alone,
nd 17 (13%) of the 131 who had WIS plus chemo-
able 4. Survival Gain Associated with Remission among Patients with
ell Transplantation
N
Achieved CR
N (%)
Median
Months to
ll patients 307 93 (30) 1.9
ays from transplantation
to relapse
<100 111 20 (18) 1.6
100-200 73 24 (33) 1.8
>200 123 49 (41) 2.2
R indicatres complete remission.
Model-based estimate of survival without attaining remission.herapy. Twelve (18%) of the 65 patients who had cLI experienced serious GVHD, compared to 21
9%) of the 242 who did not have DLI (P  .02).
ISCUSSION
This retrospective review demonstrates that re-
ission and survival rates are low among patients with
ecurrent or persistent high-risk malignancy after al-
ogeneic HCT and that outcomes are better when
alignancy recurs at longer intervals after HCT. Our
nding that the interval from HCT to relapse serves
s a powerful predictor of survival is consistent with
arlier reports from studies of patients who received
LI in association with chemotherapy for treatment
f recurrent AML after allogeneic HCT [2,26]. In the
revious studies, time intervals were categorized ac-
ording to recurrence of malignancy before or after 6
r 12 months from HCT. In the current study, the
3% incidence of remission for patients who had re-
urrence more than 1 year after HCT was lower than
he 68% incidence observed in a previous study of
atients with AML or ALL [3]. This difference might
eﬂect the selective use of HCT for patients with
ore resistant diseases in the current study. Our
-year survival estimate of 19% for patients with re-
urrence at 200 days from HCT is consistent with
he results reported by Levine et al. [2] (19%, n  29)
or patients who had chemotherapy followed by DLI
or treatment of myeloid malignancies that recurred
6 months after HCT. The new ﬁndings from our
tudy demonstrate that 3 factors contribute to the
rolonged survival associated with longer intervals
rom HCT to recurrent malignancy. These include (1)
n increased probability of remission, (2) prolonged
urvival after remission is attained, and (3) prolonged
urvival after treatment even when remission is not
ttained.
In this retrospective analysis, individual types or
ombinations of therapeutic interventions were not
ssociated with higher or lower probabilities of remis-
ion or survival. WIS, chemotherapy, and DLI were
ot assigned randomly but were selected according to
ent High-Risk Hematologic Malignancy after Allogeneic Hematopoietic
Median Months
Survived without CR*
Median Months
Survived with CR
Median Months
Gained after CR
3.0 12.4 9.4
0.8 6.7 5.9
3.0 10.5 7.5
5.1 17.7 12.6Recurr
CRlinical circumstances and the preferences of physi-
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Recurrent Leukemia after Allografting 1167ians and patients. The nonrandom assignment of
herapeutic interventions limited our ability to deter-
ine their relative importance in attaining remission
r prolonging survival.
The use of DLI did not have a measurable impact
n inducing or consolidating remission or prolonging
urvival in this study. According to widely accepted
linical practice, DLI was typically reserved for pa-
ients who were not taking immunosuppressive med-
cations and did not have clinically signiﬁcant GVHD.
n this study, the disappearance of malignant cells
fter administration of DLI in 11 of 34 patients sug-
ests that DLI can provide clinical beneﬁt, but the
roportion of patients who developed serious GVHD
24] was twice as high among patients given DLI
ompared to those not given DLI. In the end, the
rade-off between the risks of serious GVHD and the
eneﬁts of remission induction or remission prolon-
ation after DLI can be assessed only in a prospective
rial.
We also found that preceding GVHD did not
redict remission or the duration of survival after
ecurrent malignancy. This observation supports the
iew that, if GVHD is absent at the time of recurrent
alignancy, a history of GVHD should not necessar-
ly serve as a reason to avoid WIS or administration of
LI. At the same time, clinicians should keep in mind
hat WIS and DLI were associated with an increased
isk of serious GVHD.
Among patients with recurrent acute and chronic
eukemia after allogeneic HCT, second allogeneic
CT has been associated with an estimated 5-year
urvival between 12% and 28% [27-29]. A remission
uration of 6 months after the ﬁrst HCT, patient
ge20 years, and the presence of5% bone marrow
lasts at the time of second HCT have been associated
ith longer survival. The low proportion of patients
ho had second HCT in our study (6 of 307; 2%) was
elated to the selection of adults and the preponder-
nce of recurrent malignancy 200 days from HCT,
oth of which are associated with poor outcome after
econd HCT. For younger patients who have recur-
ence 200 days from HCT for treatment of high-
isk hematologic malignancy, a second allogeneic may
e a feasible and effective treatment, particularly if
emission can be induced before the second HCT.
This study has important implications for patients
ith recurrent acute leukemia or RAEB/t after allo-
eneic HCT, for their physicians who are expected to
ecommend reasonable treatment, and for directing
uture research. First, some patients who have recur-
ent malignancy within 100 days after HCT might
ish to forego further interventions in favor of pallia-
ive care if they understood that the probability of
emission is estimated at 20% and the probability of
urviving for 2 years is estimated at only 3%. Second,
linic trials that employ frequent monitoring for min-mal residual disease aimed at earlier intervention with
ess toxic antineoplastic medications should be de-
igned. Third, for patients who have recurrent malig-
ancy 200 days after HCT, attempts to induce re-
ission by administration of chemotherapy and
nduction of GVL effects remain justiﬁable, because
he probability of remission is approximately 40%,
nd the probability of survival for 2 years is approxi-
ately 20%. For this group of patients, second allo-
eneic HCT should also be considered as a treatment
ption. Clearly, however, these results leave much
oom for improvement, and well-informed patient
references should weigh very heavily in decisions
egarding treatment.
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